登录 | 注册    微信公众号  
搜索

ICAM-1信息

英文名称:Intercellular adhesion molecule-1
中文名称:细胞间粘附分子-1
靶点别称:Intercellular Adhesion Molecule 1,Cell Surface Glycoprotein P3.58,Major group rhinovirus receptor,Human Rhinovirus Receptor,CD54 Antigen,P3.58,CD54,BB2,Intercellular Adhesion Molecule-1,ICAM1,ICAM-1,Intercellular Adhesion Molecule 1 (CD54), Human Rhinovirus Receptor,Epididymis Secretory Sperm Binding Protein
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

ICAM-1 分子别名

ICAM1,BB2,CD54,P3.58

ICAM-1 分子背景

Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds.

ICAM-1 前沿进展

ICAM-1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Tocopherol acetate 生育酚醋酸酯 DSE-9912 批准上市 Ephynal, Aquasol E 静脉血栓栓塞, 动脉粥样硬化, 间歇性跛行, 血栓形成, 糖尿病视网膜病变 详情

ICAM-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Coxsackievirus A21 (Viralytics) V-937; CVA-21 临床二期 Viralytics 头颈癌, 膀胱癌, 乳腺癌, 前列腺癌, 黑色素瘤, 转移癌 详情
AIC-100 AIC-100 临床一期 Affyimmune Therapeutics 甲状腺未分化癌, 甲状腺瘤 详情
Bersanlimab BI-505 临床二期 Bioinvent International 阴燃多发性骨髓瘤, 多发性骨髓瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定